An investigation into stem cell therapy aimed at reducing neuro inflammation in patients with Alzheimer’s presymptomatic disease is underway in Uthealth Houston.
In Alzheimer’s disease, deposits of beta-amyloid and Tau lead to the structure of plaques and tangles in the brain that cause dementia. An estimated 6.9 million Americans aged 65 and older live with dementia of Alzheimer’s disease, according to the Alzheimer’s Association.
The beta-amyloid and Tau protein come first in the disease, often for decades, followed by inflammation, which leads to cell death. We have good medicines to get rid of the amyloid and to delay the progression of the disease, but not to stop. We believe that it is not stopped because the power -reducing damage caused by inflammation has been set in motion. So if we can reject both beta-amyloid and we can reduce inflammation, we may be able to reduce the risk of getting Alzheimer’s disease. “
Paul E. Schulz, MD, lead researcher, professor of neurology and director of the Neurocognitive Disorders Center in McGovern Medical School at Uthealth Houston
In this phase IB/IIA Open Label Study, the stem cells from the patient’s own fat are processed by a Sugar Land Company, Hope Biosciences and returned to the patient in four infusions for 13 weeks. The study, sponsored by Weston Brain Institute in Canada, will register 12 patients. PET image formation that is sensitive to brain inflammation will be used to determine whether stem cells reduce the main cause of the loss of brain cells in Alzheimer’s disease prior to the development of symptoms. Co-researchers are Javier Ortiz IV, PhD, university teacher Neurology, and Harshali Patel, coordinator of clinical research.
The study builds on earlier Uthealth Houston Stem cell research for traumatic brain injury (TBI) and stroke, which led to pre -clinical research in animal models of Parkinson’s disease and Alzheimer’s disease.
“With TBI and a stroke, the blood-brain barrier opens itself, so we were not sure whether the stem cells could help with a neurodegenerative disease in which the blood-brain barrier remains closed. But inflammation seems to be the final item that leads to cell death,” said Schulz, who the Rick McCord Family Family Family-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Familie crimes leads. “So researchers from Uthealth Houston started to look in mouse models of Parkinson’s disease to test whether intravenous stem cells would have an effect. They thought they were giving stem cells, the treated mice continued to act as normal mice.”
The Parkinson’s Animal Model Study was led by Claudio Soto, PhD, the Huffington Foundation Distinguished Chair in Neurology and Professor of Neurology at the McGovern Medical School.
Another study of stem cells in mice with changes in Alzheimer’s disease, also led by Soto, revealed that the memories of the animals were kept and there was a reduction in inflammation in the brain. This makes Schulz and his team very hopeful that this study will show that stem cell therapy in people with presymptomatic Alzheimer’s disease can reduce the risk of developing the clinical symptoms of the disease.
For more information about the investigation into the research page of memory disorders.
An investigation into stem cell therapy aimed at reducing neuro inflammation in patients with Alzheimer’s presymptomatic disease is underway in Uthealth Houston.
In Alzheimer’s disease, deposits of beta-amyloid and Tau lead to the structure of plaques and tangles in the brain that cause dementia. An estimated 6.9 million Americans aged 65 and older live with dementia of Alzheimer’s disease, according to the Alzheimer’s Association.
“The science-amyloid and tau protein come first in the disease, often for decades, followed by inflammation, which leads to cell death,” says Paul E. Schulz, MD, Chief Researcher, Neurology and director of the Neurocognitive Disorder Center in McGovern Medical School. “We have good drugs to get rid of the amyloid and to delay the progression of the disease, but not to stop. We believe it is not stopped because the current damage caused by inflammation has been set in motion. So if we can dismiss the beta-amyloid and reduce inflammation, we can reduce the inflammation and reduce inflammation, the risk of the disease of Alzie disease.” “”
In this phase IB/IIA Open Label Study, the stem cells from the patient’s own fat are processed by a Sugar Land Company, Hope Biosciences and returned to the patient in four infusions for 13 weeks. The study, sponsored by Weston Brain Institute in Canada, will register 12 patients. PET image formation that is sensitive to brain inflammation will be used to determine whether stem cells reduce the main cause of the loss of brain cells in Alzheimer’s disease prior to the development of symptoms. Co-researchers are Javier Ortiz IV, PhD, university teacher Neurology, and Harshali Patel, coordinator of clinical research.
The study builds on earlier Uthealth Houston Stem cell research for traumatic brain injury (TBI) and stroke, which led to pre -clinical research in animal models of Parkinson’s disease and Alzheimer’s disease.
“With TBI and a stroke, the blood-brain barrier opens itself, so we were not sure whether the stem cells could help with a neurodegenerative disease in which the blood-brain barrier remains closed. But inflammation seems to be the final item that leads to cell death,” said Schulz, who the Rick McCord Family Family Family-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Famili-Familie crimes leads. “So researchers from Uthealth Houston started to look in mouse models of Parkinson’s disease to test whether intravenous stem cells would have an effect. They thought they were giving stem cells, the treated mice continued to act as normal mice.”
The Parkinson’s Animal Model Study was led by Claudio Soto, PhD, the Huffington Foundation Distinguished Chair in Neurology and Professor of Neurology at the McGovern Medical School.
Another study of stem cells in mice with changes in Alzheimer’s disease, also led by Soto, revealed that the memories of the animals were kept and there was a reduction in inflammation in the brain. This makes Schulz and his team very hopeful that this study will show that stem cell therapy in people with presymptomatic Alzheimer’s disease can reduce the risk of developing the clinical symptoms of the disease.
For more information about the study, visit The research page of the memory disorders.